The offering provides a cash runway extension but at heavy dilution and confirms a precarious financial position. Monitor the stock price for continued pressure from the dilutive overhang and watch for any subsequent filings (e.g., 8-K closing, Q2 2026 earnings) that may reveal whether the company can achieve cash flow breakeven before the new funds are exhausted. The going concern warning is a material negative signal that may limit institutional interest.
Price Chart
Executive Summary
DarioHealth Corp. filed a 424B5 prospectus supplement for a registered direct offering of 2,451,490 shares of common stock and pre-funded warrants to purchase 1,017,499 shares, at an offering price of $6.80 per share and $6.7999 per pre-funded warrant, for total gross proceeds of approximately $23.6 million. The company explicitly discloses substantial doubt about its ability to continue as a going concern, stating that existing cash as of March 31, 2026 ($20.0 million) is insufficient to fund operations for the next 12 months. This offering provides critical near-term liquidity but at the cost of significant dilution (approximately 33% increase in shares outstanding, or up to 47% if all pre-funded warrants are exercised).
Key Facts
- Offering of 2,451,490 shares of common stock and 1,017,499 pre-funded warrants at $6.80/$6.7999 per unit.
- Total gross proceeds of approximately $23.6 million; net proceeds to company of approximately $23.1 million.
- Pre-offering shares outstanding: 7,341,866; post-offering (excluding pre-funded warrants): 9,793,356 (~33% dilution).
- Company discloses substantial doubt about ability to continue as a going concern; cash of $20.0M as of March 31, 2026 insufficient for 12 months.
- A board member purchased 14,430 shares at $6.93 per share (~$100,000).
- Offering is on a 'reasonable best efforts' basis with no minimum offering amount.
- Lock-up agreements for directors and executive officers for 30 days post-closing.
Financial Impact
Gross proceeds of $23,590,899; net proceeds of $23,108,091 after placement agent fees and expenses. Dilution of ~33% from common shares alone, up to ~47% including pre-funded warrants.
Risk Factors
- Going concern risk: company may not have sufficient capital to fund operations for 12 months even after this offering.
- Significant dilution: ~33% increase in share count (up to ~47% if all pre-funded warrants exercised).
- No minimum offering amount: actual proceeds could be less than stated if investor demand is weak.
- Reasonable best efforts basis: no guarantee the offering will fully close.
- Stock price volatility exacerbated by low trading volume and repeated equity issuances.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001104659-26-085887 |
| Document: 0001104659-26-085887-index-headers.html | 0001104659-26-085887 |
| Document: 0001104659-26-085887-index.html | 0001104659-26-085887 |
| Document: 0001104659-26-085887.txt | 0001104659-26-085887 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 22, 2026 13w ago | 424B5 | $7.47 $5.13 | ▲ +31.33% | ▲ +35.88% | $3.80 (+49.13%) |
Apr 13, 2026 27w ago | 3 | $7.56 $7.00 | ▼ −7.41% | ▼ −15.93% | $3.80 (−49.74%) |
Apr 13, 2026 28w ago | 8-K | $7.34 $7.22 | ▼ −1.63% | ▼ −10.56% | $3.80 (−48.23%) |
Mar 30, 2026 30w ago | EFFECT | $8.19 $6.15 | ▼ −24.91% | ▼ −41.40% | $3.80 (−53.60%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers